SG11201709634QA - Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity - Google Patents

Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity

Info

Publication number
SG11201709634QA
SG11201709634QA SG11201709634QA SG11201709634QA SG11201709634QA SG 11201709634Q A SG11201709634Q A SG 11201709634QA SG 11201709634Q A SG11201709634Q A SG 11201709634QA SG 11201709634Q A SG11201709634Q A SG 11201709634QA SG 11201709634Q A SG11201709634Q A SG 11201709634QA
Authority
SG
Singapore
Prior art keywords
nitrogen
inhibitory activity
hiv replication
tricyclic derivative
containing tricyclic
Prior art date
Application number
SG11201709634QA
Other languages
English (en)
Inventor
Yoshinori Tamura
Takashi Kawasuji
Shuichi Sugiyama
Akira Matsumura
Toshiyuki Akiyama
Yutaka Tomida
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of SG11201709634QA publication Critical patent/SG11201709634QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06Peri-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201709634QA 2015-05-29 2016-05-27 Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity SG11201709634QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015109547 2015-05-29
JP2015170222 2015-08-31
JP2015223036 2015-11-13
JP2016054215 2016-03-17
PCT/JP2016/065702 WO2016194806A1 (fr) 2015-05-29 2016-05-27 Dérivé tricyclique contenant de l'azote présentant une activité inhibitrice de la réplication du vih

Publications (1)

Publication Number Publication Date
SG11201709634QA true SG11201709634QA (en) 2017-12-28

Family

ID=57442245

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201709634QA SG11201709634QA (en) 2015-05-29 2016-05-27 Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity

Country Status (16)

Country Link
US (2) US10494380B2 (fr)
EP (1) EP3305789A4 (fr)
JP (2) JP6614585B2 (fr)
KR (1) KR20180011267A (fr)
CN (2) CN111138458A (fr)
AU (1) AU2016271762B2 (fr)
BR (1) BR112017025367A2 (fr)
CA (1) CA2987384A1 (fr)
HK (1) HK1253539A1 (fr)
IL (1) IL255580B (fr)
MA (1) MA43120A (fr)
MX (1) MX2017015256A (fr)
RU (1) RU2720145C2 (fr)
SG (1) SG11201709634QA (fr)
TW (1) TWI700284B (fr)
WO (1) WO2016194806A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970282B1 (fr) 2013-03-15 2019-08-21 Incyte Holdings Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de protéine bet
EP3019502B1 (fr) 2013-07-08 2017-05-17 Incyte Holdings Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de protéines bet
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
EP4234554A3 (fr) 2016-06-20 2023-12-27 Incyte Corporation Formes cristallines solides d'un inhibiteur bet
JP7290356B2 (ja) * 2019-01-23 2023-06-13 アビスコ セラピューティクス カンパニー リミテッド 1,2,3,4-テトラヒドロキノキサリン誘導体、その製造方法および使用
TW202133858A (zh) 2019-11-28 2021-09-16 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112409493B (zh) * 2020-08-12 2022-09-30 浙江工业大学 一种重组融合酶及其在乙醛酸甲酯合成中的应用
CN114075212B (zh) * 2020-08-14 2023-05-12 江苏恒瑞医药股份有限公司 稠合三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505451A (ja) 1996-02-21 2000-05-09 ダーウィン・ディスカバリー・リミテッド キノロン類およびこれらの治療的使用
AU710825B2 (en) * 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
US5792774A (en) 1996-02-21 1998-08-11 Chiroscience Limited Quinolones and their therapeutic use
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
WO2002012239A1 (fr) * 2000-08-08 2002-02-14 Sanofi-Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
JP2004256531A (ja) * 2003-02-07 2004-09-16 Takeda Chem Ind Ltd 三環性化合物、その製造法および用途
EP1593681A4 (fr) 2003-02-07 2007-09-05 Takeda Pharmaceutical Compose tricyclique, procede de production et utilisation dudit compose
AR056918A1 (es) 2005-01-10 2007-11-07 Tibotec Pharm Ltd 2-oxo-3-ciano-1,6a-diaza-tetrahidro-fluorantenos 1,5,6-sustituidos, proceso de preparacion del compuesto y composicion farmaceutica
MX2008001152A (es) 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
SI2220076T1 (sl) 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
WO2009062308A1 (fr) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
MA34397B1 (fr) * 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CA2817896A1 (fr) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibiteurs de la replication du vih
EP2640705A2 (fr) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Nouveaux composés antiviraux
WO2012102985A1 (fr) 2011-01-24 2012-08-02 Glaxosmithkline Llc Composés d'isoquinoléine et procédés pour traiter le vih
EP2508511A1 (fr) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2511273B8 (fr) * 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
CA2833377C (fr) 2011-04-21 2019-02-12 Gilead Sciences, Inc. Composes benzothiazoles et leur utilisation pharmaceutique
WO2013002357A1 (fr) 2011-06-30 2013-01-03 塩野義製薬株式会社 Inhibiteur de réplication du vih
ES2624984T3 (es) 2011-07-15 2017-07-18 Viiv Healthcare Uk Limited Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013043553A1 (fr) 2011-09-22 2013-03-28 Glaxosmithkline Llc Composés pyrrolopyridinones et méthodes de traitement du vih
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
PT2781519T (pt) 2011-11-15 2019-12-17 St Pharm Co Ltd Novo derivado de pirrolopiridina antiviral e um método de produção do mesmo
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013157622A1 (fr) 2012-04-19 2013-10-24 塩野義製薬株式会社 Inhibiteur de la réplication du vih
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CA2876370A1 (fr) * 2012-07-12 2014-01-16 Viiv Healthcare Uk Limited Composes et procedes de traitement du vih
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2716639A1 (fr) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2716632A1 (fr) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2719685A1 (fr) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
TW201441197A (zh) * 2013-01-31 2014-11-01 Shionogi & Co Hiv複製抑制劑
CN105008358B (zh) 2013-03-13 2017-12-29 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
WO2015126765A1 (fr) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2015147247A1 (fr) 2014-03-28 2015-10-01 塩野義製薬株式会社 Dérivé tricyclique présentant une activité inhibitrice de la réplication du vih
EP3144311A4 (fr) 2014-05-16 2018-01-03 Shionogi & Co., Ltd. Dérivé hétérocyclique tricyclique présentant un effet d'inhibition de la réplication du vih
WO2015179448A1 (fr) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Composés thérapeutiques
JP2017521428A (ja) 2014-07-08 2017-08-03 ヴィーブ ヘルスケア ユーケー リミテッド ウイルス感染症の治療に使用するためのイソインドリン誘導体
UY36221A (es) 2014-07-22 2016-02-29 Viiv Healthcare Uk Ltd Derivados de isoindolinona
AU2015306779B2 (en) 2014-08-27 2017-11-02 VIIV Healthcare UK (NO.5) Ltd Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
TW201720798A (zh) 2015-09-17 2017-06-16 Viiv醫療保健英國有限公司 苯并氮呯衍生物
EP3383862A1 (fr) 2015-12-04 2018-10-10 ViiV Healthcare UK Limited Dérivés d'isoindoline
JP2018536001A (ja) 2015-12-04 2018-12-06 ヴィーブ ヘルスケア ユーケー リミテッド イソインドリン誘導体
WO2017093930A1 (fr) 2015-12-04 2017-06-08 Viiv Healthcare Uk Limited Dérivés d'isoindoline
JP2019501143A (ja) 2015-12-04 2019-01-17 ヴィーブ ヘルスケア ユーケー リミテッド テトラヒドロイソキノリン誘導体

Also Published As

Publication number Publication date
AU2016271762B2 (en) 2020-01-23
JPWO2016194806A1 (ja) 2018-03-22
MA43120A (fr) 2018-09-05
RU2720145C2 (ru) 2020-04-24
CA2987384A1 (fr) 2016-12-08
CN107922423A (zh) 2018-04-17
IL255580A (en) 2018-01-31
US20180162876A1 (en) 2018-06-14
US20200055873A1 (en) 2020-02-20
HK1253539A1 (zh) 2019-06-21
BR112017025367A2 (pt) 2018-08-07
WO2016194806A1 (fr) 2016-12-08
KR20180011267A (ko) 2018-01-31
TW201706275A (zh) 2017-02-16
IL255580B (en) 2020-11-30
CN111138458A (zh) 2020-05-12
AU2016271762A1 (en) 2017-11-30
EP3305789A1 (fr) 2018-04-11
CN107922423B (zh) 2020-10-27
JP6614585B2 (ja) 2019-12-04
TWI700284B (zh) 2020-08-01
JP6797464B2 (ja) 2020-12-09
RU2017145082A (ru) 2019-07-01
MX2017015256A (es) 2018-02-19
EP3305789A4 (fr) 2018-11-21
RU2017145082A3 (fr) 2019-10-24
US10494380B2 (en) 2019-12-03
US10870661B2 (en) 2020-12-22
JP2020097568A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
HK1253539A1 (zh) 具有hiv複製抑制作用的含氮三環性衍生物
IL291598A (en) History of benzodiazepine cytotoxicity
HK1245253A1 (zh) Parg抑制化合物
EP3193667A4 (fr) Étagères modulaires
ZA201900019B (en) Pharmaceutical combinations
PL3310784T3 (pl) Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
GB2529856B (en) Modular furniture system
IL257808B (en) decarboxylation without water
HK1253011A1 (zh) 聯合hiv療法
EP3144311A4 (fr) Dérivé hétérocyclique tricyclique présentant un effet d'inhibition de la réplication du vih
PL3531872T3 (pl) Mebel
HK1245796A1 (zh) 黃嘌呤衍生物
PT3187071T (pt) Gaveta
EP3174864A4 (fr) Composés inhibiteurs de vmat
GB201612404D0 (en) Vdu
GB201607978D0 (en) Inhibitory compounds
AU201613667S (en) Log splitter
GB201610579D0 (en) Furniture
AU2015904138A0 (en) Saddle Shelving
GB201517291D0 (en) Modular furniture system
GB201509287D0 (en) Modular furniture system
GB201402369D0 (en) Pair Pursuit